TEER

TRICLIP™ TRANSCATHETER TRICUSPID VALVE REPAIR SYSTEM

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.1

TEER

TRICLIP™ TRANSCATHETER TRICUSPID
VALVE REPAIR SYSTEM

TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.1

THE STANDARD OF
 CARING FOR TR

 

The TriClip Transcatheter Edge-to-Edge Repair (TEER) system is the only TEER device intentionally designed for the tricuspid valve. With stable navigation and precise delivery,2-5 TriClip TEER is the only tricuspid device proven to reduce risk of heart failure hospitalization and improve quality of life, relative to optimal medical therapy.6 In both randomized and real-world studies, TriClip TEER has proven:

  • Exceptional safety profile9,10
  • Maximized effectiveness in tricuspid regurgitation (TR) reduction6,7
  • Life Changing Improvements to heart failure hospitalization risk and quality of life6,7,9,10

A state-of-the-art treatment option for patients at intermediate or greater risk for surgery

TriClip TEER is a low-risk,11 non-surgical treatment option for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation, despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.2

  • Transcatheter beating heart procedure - no cardiopulmonary bypass
  • Allows for real-time positioning and repositioning to optimize TR reduction
  • Femoral venous access
  • Can be used in a standard cath lab or hybrid room
  • No pre-procedural CT required
  • Fast recovery times; many patients go home the next day8
  • Reduced HFH & QoL12
    • Shortness of breath
    • Peripheral edema
    • Ascites
    • Fatigue
    • Declining exercise capacity
       
  • Current treatment options have limitations

    Medical therapy for TR has little impact on TR reduction – 2 year data6

     
    66%

    of patients with severe functional tricuspid regurgitation die within 5 years of medical management13

     


    Most patients receive medical management until right heart failure or end-organ dysfunction appears.14

  • Surgery is high risk and often not optimal15,16

    Surgery for TR is uncommon. Factors prohibiting surgery include:

    • Limited clinical evidence15
    • Multiple comorbidities15
    • Advanced age15
    • High rate of adverse events17,18


    Long-term survival estimates for patients undergoing surgical tricuspid valve replacement or repair11

EXCEPTIONAL SAFETY9,10

MAXIMIZED EFFECTIVENESS6,7

LIFE-CHANGING IMPACT6,7,9,10

The TriClip™ G5 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery2,5
for complex conditions.9,6

Delivery Catheter (DC) Handle

  • Handle has integrated gripper levers and reduced flush volume.

  • Arm Positioner

  • Hard stop within arm positioner in open direction.

  • Release Pin

  • Finger hold to pull and initiate clip deployment.

  • Lock Line Release Latch

  • Releases one end of lock line at time of deployment.

  • Lock Knob

  • Discrete lock and unlock positions and no blue line.

  • Delivery System (DS) Attach

  • Spring-loaded attachment slides into stabilizer rail. Replaces black screw.

  • Stabilizer

  • Stabilizer rail and handles to support the movement of the delivery system.

  • Guide Attach

  • Spring-loaded attachment with pins for insertion into stabilizer dock. Replaces black screws and the need to tighten screw to secure position.

  • Guide Attachment Braking System

  • Allows for adjustable guide positioning and holds guide catheter position. Replaces black screw.

  • Built-in DC Fastener

  • Rotation of fastener counterclockwise secures delivery catheter. Replaces black screw.

  • EPIC™ SUPRA AORTIC STENTED  TISSUE VALVE FEATURES
    1
    2
    3
    4
    5
    6
    7
    8
      • Provides stability and precision during steering and positioning
      • Multiaxis steering to enable navigation across all lines of coaptation
    1. Flexes and extends delivery catheter to steer down to the valve plane
    2. Enables movement in septal or lateral direction
    3. Straightens and curves guide for height adjustment above the valve
    4. Designed for the tricuspid anatomy

      • Provides adequate height over the valve
      • Maintains coaxial position during steering and positioning
      • Allows sweeping away from the septum to optimize delivery catheter while maintaining perpendicularity to the valve plane
    5. Designed for direct access to the tricuspid valve
    6. Confirm and optimize leaflet capture
    7. Implant and gripper line detachment

    EASY HANDLING 

    • Quick, secure docking with spring-loaded attachments for easy connection
    • Precise locking with binary lock knob to support consistent performance
    • Built-in fastener for easy securement of the DC

    PRECISE POSITIONING 

    • New guide attachment with braking system maintains desired positioning for enhanced control
    • Controlled movement with redesigned stabilizer rail and handles
    • Responsive new handle design capable of delivering 1:1 rotation

    INTUITIVE DEPLOYMENT 

    • New lock knob offers easy and straightforward lock line release and removal
    • Hard stop within arm positioner reduces dependence on visual indicators for more control
    • Disconnect with ease using new release pin with finger hold to initiate deployment

    Test(s) performed by and data on file at Abbott.

    • Building on a legacy of unmatched TEER expertise19

      TriClip™ implants use the same proven leaflet repair technology as our MitraClip™ Transcatheter Edge-to-Edge Repair (TEER) implants. TriClip TEER is the clip-based technology physicians know and trust, with a delivery system uniquely designed for the tricuspid valve.

      TriClip implant features:1

      • Elgiloy® implants with nitinol grippers
      • Polyester cover designed to promote tissue growth
      • Magnetic resonance conditional to 3 Tesla
         

      Static magnetic field of 1.5 T or 3 T; maximum spatial gradient in static field of 4000 gauss/cm; maximum whole-body averaged specific absorption rate (SAR) of 2 W/kg for 60 minutes of continuous radiofrequency.
       

    • Optimized leaflet capture

      Optimized leaflet capture for consistent TR reduction with the TriClip G5 TEER System

      • Wide grasp opening allows full leaflet insertion20
      • Designed to distribute retention forces along the entire inserted leaflet length21
      • Four or six rows of short frictional elements designed to provide atraumatic leaflet engagement21
    • Broad range of sizes for tailored treatment

      Four implant sizes are available for patient-specific therapy with the TriClip G5 TEER System.1

    CLINICAL DATA

    See the latest clinical data for the TriClip Transcatheter Tricuspid Valve Repair System

    See Clinical Data


    MAT-2006554 v11.0 | Item approved for OUS use only.

    Copyright © 2025 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
    Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
    Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
    Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
    No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

    MAT-2000631 v21.0 | Item approved for OUS use only.

    YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

    YOU ARE ABOUT TO LEAVE
    www.structural­heart.abbott

    You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

    +